Collegium announces $35 million accelerated share repurchase program
Seeking Alpha News (Mon, 13-May 9:06 AM ET)
Collegium Announces $35 Million Accelerated Share Repurchase Program
Globe Newswire (Mon, 13-May 8:00 AM ET)
Collegium downgraded by Piper Sandler over valuation
Seeking Alpha News (Fri, 10-May 1:12 PM ET)
Collegium Pharmaceutical (COLL) Gets a Buy from Truist Financial
TipRanks (Fri, 10-May 8:09 AM ET)
TipRanks (Fri, 10-May 5:10 AM ET)
Collegium Reports First Quarter 2024 Financial Results
Globe Newswire (Thu, 9-May 4:02 PM ET)
Collegium Announces CEO Transition
Globe Newswire (Thu, 9-May 4:01 PM ET)
Globe Newswire (Mon, 29-Apr 8:00 AM ET)
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
Globe Newswire (Thu, 25-Apr 8:00 AM ET)
Globe Newswire (Thu, 11-Apr 8:00 AM ET)
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Collegium Pharmaceutical trades on the NASDAQ stock market under the symbol COLL.
As of May 15, 2024, COLL stock price climbed to $33.65 with 80,553 million shares trading.
COLL has a beta of 0.53, meaning it tends to be less sensitive to market movements. COLL has a correlation of 0.04 to the broad based SPY ETF.
COLL has a market cap of $1.10 billion. This is considered a Small Cap stock.
Last quarter Collegium Pharmaceutical reported $145 million in Revenue and $1.45 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.70.
In the last 3 years, COLL stock traded as high as $40.95 and as low as $14.04.
The top ETF exchange traded funds that COLL belongs to (by Net Assets): CALF, IJR, VTI, IWM, VXF.
COLL has outperformed the market in the last year with a return of +45.9%, while the SPY ETF gained +29.6%. However, in the most recent history, COLL shares have underperformed the stock market with its stock returning +2.3% in the last 3 month period and -8.9% for the last 2 week period, while SPY has returned +6.0% and +4.9%, respectively.
COLL support price is $32.54 and resistance is $34.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COLL stock will trade within this expected range on the day.